Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data
Efficacy Data On Casirivimab/Imdevimab In Mutant Strains Forthcoming
Executive Summary
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
You may also be interested in...
Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.
Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.